Patents by Inventor Won Jun Oh

Won Jun Oh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240185068
    Abstract: Disclosed is a method for performing a membership inference attack against generative models according to one embodiment of the present invention.
    Type: Application
    Filed: November 30, 2023
    Publication date: June 6, 2024
    Inventors: Jun Beom HUR, Won Jun OH, Bo Sung YANG, Gyeong Sup LIM
  • Patent number: 10584371
    Abstract: The present invention relates to a method for lyophilizing a composition for multiple target nucleic acid sequence amplification reaction and a lyophilizate prepared by the method. The present method is very effective in lyophilizing a composition containing a high concentration of oligonucleotides. The lyophilizates prepared by the present invention exhibits excellent properties in terms of both sensitivity and specificity, equivalent performance capacity to conventional liquid formulation and furthermore remarkable storage stability. Accordingly, the lyophilizates prepared by the present invention would be very useful in diagnosis.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 10, 2020
    Assignee: SEEGENE, INC.
    Inventors: Jong Yoon Chun, Won Jun Oh
  • Publication number: 20180023117
    Abstract: The present invention relates to a method for lyophilizing a composition for multiple target nucleic acid sequence amplification reaction and a lyophilizate prepared by the method. The present method is very effective in lyophilizing a composition containing a high concentration of oligonucleotides. The lyophilizates prepared by the present invention exhibits excellent properties in terms of both sensitivity and specificity, equivalent performance capacity to conventional liquid formulation and furthermore remarkable storage stability. Accordingly, the lyophilizates prepared by the present invention would be very useful in diagnosis.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 25, 2018
    Inventors: Jong Yoon CHUN, Won Jun OH
  • Patent number: 7053262
    Abstract: The mammary gland-specific expression systems developed by the present inventors, named pGbc, pGbc_L and pGbc_S were deposited under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure in the Korean Collection for Type Cultures (KCTC), Korean Research Institute of Bioscience and Biotechnology at 52, Oun-dong, Yusong-Ku, Taejon 305–333, Republic of Korea, on Aug. 17, 1998, and the accession deposit Nos. KCTC 0515BP, 0514BP and 0513BP were issued, respectively. All restructions on the availability to the public of the deposited materials will be irrevocably removed upon the granting of a patent.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: May 30, 2006
    Assignee: Hanmi Pharm Co., Ltd.
    Inventors: Ook Joon Yoo, Kyung Kwang Lee, Young Mahn Han, Sun Jung Kim, Hae Young Jeong, Jung Ho Ko, Won Jun Oh
  • Patent number: 6635474
    Abstract: There are disclosed mammary gland tissue-specific expression systems using the promoter site for the &bgr;-casein gene of Korean native goats, by use of which physiological activating substances can be produced. In each of the expression systems, that is, novel plasmids pGbc, pGbc_L and pGbc_S (deposition Nos. KCTC 0515BP, 0514BP and 0513BP, respectively), a &bgr;-casein gene expression-regulating region, a physiological activating substance gene and a termination-regulating region are linked. Human granulocyte colony stimulating factor (hG-CSF) or human granulocyte macrophage colony stimulating factor (hGM-CSF) can be produced in HC11 cells, a mouse mammary gland tissue-derived cell line, and in the milk secreted from the transgenic mice by use of a hG-CSF or hGM-CSF gene-carrying pGbc, pGbc_L or pGbc_S in transfection into cell and microinjection to mouse. The proteins are those which experience the posttranslational modification and maintain their normal activity in the human body.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: October 21, 2003
    Assignee: Hanmi Pharm Co., Ltd
    Inventors: Ook Joon Yoo, Kyung Kwang Lee, Young Mahn Han, Sun Jung Kim, Hae Young Jeong, Jung Ho Ko, Won Jun Oh
  • Publication number: 20030145342
    Abstract: There are disclosed mammary gland tissue-specific expression systems using the promoter site for the &bgr;-casein gene of Korean native goats, by use of which physiological activating substances can be produced. In each of the expression systems, that is, novel plasmids pGbc, pGbc_L and pGbc_S (deposition Nos. KCTC 0515BP, 0514BP and 0513BP, respectively), a &bgr;-casein gene expression-regulating region, a physiological activating substance gene and a termination-regulating region are linked. Human granulocyte colony stimulating factor (hG-CSF) or human granulocyte macrophage colony stimulating factor (hGM-CSF) can be produced in HC11 cells, a mouse mammary gland tissue-derived cell line, and in the milk secreted from the transgenic mice by use of a hG-CSF or hGM-CSF gene-carrying pGbc, pGbc_L or pGbc_S in transfection into cell and microinjection to mouse. The proteins are those which experience the posttranslational modification and maintain their normal activity in the human body.
    Type: Application
    Filed: January 17, 2003
    Publication date: July 31, 2003
    Inventors: Ook Joon Yoo, Kyung Kwang Lee, Young Mahn Han, Sun Jung Kim, Hae Young Jeong, Jung Ho Ko, Won Jun Oh